Citadel Advisors’s Epirus Biopharmaceuticals EPRS Stock Holding History
Bought
Maintained
Sold
Other funds holding EPRS
Citadel Advisors's EPRS Position: Q2 2016 in Review
Citadel Advisors sold out of Epirus Biopharmaceuticals (EPRS) in Q2 2016, closing a stake of 10,359 shares — an estimated $28K sold.
Citadel Advisors first reported a position in EPRS in Q2 2015 and held it in 3 quarters. The position peaked at $230K in Q2 2015. 32 funds tracked by Wall St. Rank hold EPRS as of Q2 2016.
- Citadel Advisors reported no remaining Epirus Biopharmaceuticals position as of Q2 2016 after selling out during the quarter.
- Citadel Advisors sold 10,359 Epirus Biopharmaceuticals shares in Q2 2016, an estimated $28K.
- Citadel Advisors first reported a position in Epirus Biopharmaceuticals in Q2 2015 and held it in 3 quarters.
- Citadel Advisors's Epirus Biopharmaceuticals position peaked at $230K in Q2 2015.
- 32 funds tracked by Wall St. Rank held Epirus Biopharmaceuticals as of Q2 2016.
Based on Citadel Advisors's 13F filing for Q2 2016, filed 12 Aug 2016.